LONDON, UK I 11, 2024 I GSK plc (LSE/NYSE: GSK) today announced that it has completed the primary objective data analysis from the phase II part of ...

Berenberg Bank analyst Kerry Holford maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a price target ...

GSK announces phase I/II therapeutic herpes simplex virus vaccine trial fails to meet the study’s primary efficacy objective: London, UK Thursday, September 12, 2024, 09:00 Hrs ...

GSK has announced that Part II of the Phase I/II TH HSV REC-003 trial of its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, did not meet its primary efficacy endpoint. The ...

Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints Vaccine candidate based on CureVac's ...

Drugmaker GSK said on Wednesday that primary objective data analysts from a phase II trial of its early-stage therapeutic ...

"Given the unmet medical need and burden associated with genital herpes, innovation in this area is still needed. GSK intends to evaluate the totality of all these data and other studies to progress ...

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

PRESS RELEASECHARM Therapeutics appoints Dr Beverley Carr as Chief Business OfficerHighly experienced dealmaker to lead CHARM ...

GSK's findings support the progression of ... The company is expanding its mRNA platform to address other infectious diseases and therapeutic areas such as cancer. This report is based on a ...

GlaxoSmithKline Pharmaceuticals Ltd. engages ... Its prescription medicines range across therapeutic areas such as anti-infective, dermatology, gynecology, diabetes, cardiovascular disease and ...